Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

Dimopoulos Meletios A. and Moreau Philippe and Palumbo Antonio and Joshua Douglas and Pour Ludek and Hájek Roman and Facon Thierry and Ludwig Heinz and Masszi Tamás and Kollaborációs szervezet: ENDEAVOR investigators and Horváth Noémi and Egyed Miklós and Masszi Tamás and Szomor Árpád and Borbényi Zita and Illés Árpád and Kovácsovics Tibor (kollab. közrem.): Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
LANCET ONCOLOGY, 17 (1). pp. 27-38. ISSN 1470-2045 (2016)

[thumbnail of Dimopoulos.pdf] Text
Dimopoulos.pdf - Published Version

Download (409kB)
Item Type: Journal Article
Szerzők száma: 231
Journal or Publication Title: LANCET ONCOLOGY
Date: 2016
Volume: 17
Number: 1
Page Range: pp. 27-38
ISSN: 1470-2045
Faculty/Unit: Faculty of Medicine
Institution: Szegedi Tudományegyetem
Language: English
MTMT rekordazonosító: 3012971
DOI azonosító: https://doi.org/10.1016/S1470-2045(15)00464-7
Date Deposited: 2022. Apr. 20. 08:50
Last Modified: 2022. Apr. 20. 08:50
URI: http://publicatio.bibl.u-szeged.hu/id/eprint/24148
Web of Science® Times Cited: 572 View citing articles in Web of Science®

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year